Key Takeaways

  • A small chip inserted under the skin can monitor patients after common forms of stroke to predict those at high risk of a recurrent stroke.
  • The chip may help physicians identify patients who could benefit from stroke prevention therapies.

We believe that patients similar to those in this trial should now undergo long-term monitoring with an insertable cardiac monitor.

Lee H. Schwamm, MD
C. Miller Fisher Chair of Vascular Neurology, Massachusetts General Hospital

BOSTON – For patients who have experienced certain common types of stroke, a small chip inserted under the skin may help physicians predict their likelihood of experiencing a second stroke, and therefore their likelihood of benefiting from preventive therapy. The findings come from a recent clinical trial published in the Journal of the American Medical Association and led by investigators at Massachusetts General Hospital (MGH) and Northwestern University Feinberg School of Medicine.

Each year, approximately 800,000 strokes occur in the United States, and as many as one-fourth occur in people who experienced a previous stroke. Investigators have been searching for ways to identify patients who are likely to experience a recurrent stroke, as these individuals could be candidates for taking certain medications such as blood thinners. One group of patients who face an elevated risk of recurrent strokes are those with atrial fibrillation—an irregular and often rapid heart rate—that often goes undetected and untreated. (Irregular heartbeats can allow blood to pool in the heart, which can cause clots to form and travel to the brain.)

Recent research has shown that a small chip inserted under the skin can monitor the heart rate and rhythm, and help physicians detect atrial fibrillation in patients who previously experienced what’s called a cryptogenic stroke, one with no identified cause despite thorough patient testing. Now investigators have tested the chip—less than 1¾″ long and 1/6″ thick and called an insertable cardiac monitor—in patients who experienced a stroke caused by narrowing of a large artery like the carotid artery, or blockage of a small artery deep in the brain where atrial fibrillation would be unexpected.

In the Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE AF) trial, 492 patients were randomized and completed 12 months of follow-up after receiving either an insertable cardiac monitor within 10 days of an initial stroke or usual care consisting of external cardiac monitoring through electrocardiograms or other tracking methods.

The chip detected atrial fibrillation in 12.1% of patients, compared with 1.8% detected through usual care. The team noted that the episodes of atrial fibrillation were not brief, with most lasting at least one hour. Most stroke experts would recommend that patients with this degree of atrial fibrillation start taking blood thinners to prevent a future stroke.   

“We found that a significant minority of patients with stroke not thought to be related to atrial fibrillation actually have atrial fibrillation, but we can only find it with an implantable monitor,” says lead author Richard A. Bernstein, MD, PhD, a professor of Neurology at Northwestern University Feinberg School of Medicine.

Adds senior author Lee H. Schwamm, MD, C. Miller Fisher Chair of Vascular Neurology at MGH: “Based on the study findings, we believe that patients with stroke who are similar to those in the STROKE AF Trial should now undergo long-term cardiac monitoring with an insertable cardiac monitor to identify unsuspected atrial fibrillation.”

Schwamm notes that for every eight patients monitored, clinicians could expect to find atrial fibrillation in one of them in the first year. “This could dramatically change the treatment recommendations by their doctor,” he says.

Next steps in this research include identifying patient factors that predict the development of atrial fibrillation and the duration and extent of the arrhythmia. Additional studies are being explored to further understand the association of silent atrial fibrillation and recurrent stroke of all types.

Schwamm is professor of Neurology at Harvard Medical School and vice president of Virtual Care at Mass General Brigham. Co-authors are Hooman Kamel, MD, of Weill Cornell Medicine in New York City; Christopher B. Granger, MD, and Jonathan P. Piccini, MD, of Duke University Medical Center; Pramod P. Sethi, MD, of Cone Health Stroke Center and Guilford Neurologic Research Associates in Greensboro, North Carolina; Jeffrey M. Katz, MD, of North Shore University Hospital in Manhasset, New York; and Carola Alfaro Vives, MS, Paul D. Ziegler, MS, and Noreli C. Franco, PhD, of Medtronic.

This study was supported by Medtronic.

About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."